DNA

Ginkgo Bioworks is a leading horizontal platform for cell programming, designed to enable the biological production of products across diverse markets including food, agriculture, pharmaceuticals, and industrial chemicals. The company's platform utilizes advanced automation, data analytics, and software to program cells as easily as computers, offering 'Biology-as-a-Service' to its partners. Ginkgo's 'Foundry' and 'Codebase' allow for the rapid design, build, and test of organisms, significantly reducing the cost and time of biological R&D. The company operates through a partnership model, taking equity or royalty stakes in the products developed on its platform rather than developing its own internal drug pipeline. Headquartered in Boston, Ginkgo is a key player in the synthetic biology space and is listed on the NYSE under the ticker DNA. Through strategic acquisitions like Zymergen, the company continues to expand its scale and technical capabilities in the bioengineering space. Its diverse portfolio of collaborations includes major pharmaceutical companies such as Pfizer, Merck, and Biogen.